

This week in therapeutics

| Indication | Target/marker/pathway | Summary | Licensing status | Publication and contact information |
|---------------|--|---|---|---|
| Cancer | | | | |
| Breast cancer | Ribosomal protein S6 kinase 90 kDa polypeptide 2 (RPS6KA2; RSK3); RPS6KA6 (RSK4); phosphoinositide-3 kinase (PI3K) | Cell culture and mouse studies suggest inhibiting RSK3 and RSK4 could be useful for treating breast cancers resistant to PI3K inhibitors. In cultured breast cancer cells, vector-mediated overexpression of RSK3 or RSK4 increased cell survival in the presence of PI3K pathway inhibitors compared with a control vector. In mouse xenograft models for human breast cancer, vector-mediated overexpression of RSK3 or RSK4 decreased tumor sensitivity to PI3K inhibitors compared with no overexpression. Next steps include identifying selective inhibitors of RSK3 and RSK4 and evaluating them in PI3K inhibitor-resistant tumors. | Unpatented; licensing status not applicable | Serra, V. <i>et al.</i> <i>J. Clin. Invest.</i> ; published online May 1, 2013; doi:10.1172/JCI66343 Contact: So Young Kim, Duke University, Durham, N.C. e-mail: soyoung.kim@duke.edu Contact: José Baselga, Memorial Sloan-Kettering Cancer Center, New York, N.Y. e-mail: baselgaj@mskcc.org |
| | | SciBX 6(20); doi:10.1038/scibx.2013.486 Published online May 23, 2013 | | |